[{"orgOrder":0,"company":"Ois\u00edn Biotechnologies","sponsor":"AbbVie Ventures","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ois\u00edn Biotechnologies","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ois\u00edn Biotechnologies \/ AbbVie Ventures","highestDevelopmentStatusID":"14","companyTruncated":"Ois\u00edn Biotechnologies \/ AbbVie Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Oisín Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : The proceeds will be used to advance company's pipeline of therapies for age-related diseases toward clinical development by eliminating unwanted fat cells and build muscle mass to address frailty.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 24, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Preclinical

                          Sponsor : AbbVie Ventures

                          Deal Size : $15.0 million

                          Deal Type : Series A Financing

                          blank